Active-site inhibitors of HIV-1 PR (protease) block viral replication by preventing viral maturation. However, HIV-1 often develops resistance to active-site inhibitors through multiple mutations in PR and therefore recent efforts have focused on inhibiting PR dimerization as an alternative approach. Dimerization inhibitors have been identified using kinetic analysis, but additional characterization of the effect of these inhibitors on PR by physical methods has been difficult. In the present study, we identified a PRMDR (multi-drug-resistant HIV-1 PR) that was highly resistant to autoproteolysis. Using this PR and a novel size-exclusion chromatographic approach that incorporated fluorescence and MS detection, we were able to demonstrate inhibition of dimerization using P27 (peptide 27), a peptide dimerization inhibitor of PR previously identified on the basis of kinetic analysis. Incubation of PRMDR with P27, or other dimerization inhibitors, led to a dose- and time-dependent formation of PR monomers based on the change in elution time by size exclusion and its similar elution time to engineered forms of monomeric PR, namely PRT26A and glutathionylated PR. In contrast, incubation of PRMDR with a potent active-site inhibitor did not change the elution time for the PRMDR dimer. The monomeric PR induced by P27 had fluorescent characteristics which were consistent with unfolded PR. Structure–activity studies identified the active regions of P27 and experiments were performed to examine the effect of other dimerization inhibitors on PR. The present study is the first characterization of dimerization inhibition of PRMDR, a prime target for these inhibitors, using a novel size-exclusion chromatographic approach.
Skip Nav Destination
Close
Article navigation
April 2009
- Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Research Article|
March 27 2009
Analysis and characterization of dimerization inhibition of a multi-drug-resistant Human Immunodeficiency Virus Type 1 protease using a novel size-exclusion chromatographic approach
David A. Davis
;
David A. Davis
1
*HIV and AIDS Malignancy Branch, Retrovirology Disease Section, Center for Cancer Research, National Cancer Institute, Building 10, Room 6N106, NIH (National Institutes of Health), Bethesda, MD 20892, U.S.A.
1To whom correspondence should be addressed (email dadavis@helix.nih.gov).
Search for other works by this author on:
Irene R. Tebbs
;
Irene R. Tebbs
*HIV and AIDS Malignancy Branch, Retrovirology Disease Section, Center for Cancer Research, National Cancer Institute, Building 10, Room 6N106, NIH (National Institutes of Health), Bethesda, MD 20892, U.S.A.
Search for other works by this author on:
Sarah I. Daniels
;
Sarah I. Daniels
*HIV and AIDS Malignancy Branch, Retrovirology Disease Section, Center for Cancer Research, National Cancer Institute, Building 10, Room 6N106, NIH (National Institutes of Health), Bethesda, MD 20892, U.S.A.
Search for other works by this author on:
Stephen J. Stahl
;
Stephen J. Stahl
†The Protein Expression Laboratory, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Building 6B, Room 1B130, NIH (National Institutes of Health), Bethesda, MD 20892, U.S.A.
Search for other works by this author on:
Joshua D. Kaufman
;
Joshua D. Kaufman
†The Protein Expression Laboratory, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Building 6B, Room 1B130, NIH (National Institutes of Health), Bethesda, MD 20892, U.S.A.
Search for other works by this author on:
Paul Wingfield
;
Paul Wingfield
†The Protein Expression Laboratory, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Building 6B, Room 1B130, NIH (National Institutes of Health), Bethesda, MD 20892, U.S.A.
Search for other works by this author on:
Michael J. Bowman
;
Michael J. Bowman
‡Department of Chemistry, Purdue University, West Lafayette, IN 47907, U.S.A.
Search for other works by this author on:
Jean Chmielewski
;
Jean Chmielewski
‡Department of Chemistry, Purdue University, West Lafayette, IN 47907, U.S.A.
Search for other works by this author on:
Robert Yarchoan
Robert Yarchoan
*HIV and AIDS Malignancy Branch, Retrovirology Disease Section, Center for Cancer Research, National Cancer Institute, Building 10, Room 6N106, NIH (National Institutes of Health), Bethesda, MD 20892, U.S.A.
Search for other works by this author on:
Biochem J (2009) 419 (2): 497–506.
Article history
Received:
October 14 2008
Revision Received:
January 15 2009
Accepted:
January 16 2009
Accepted Manuscript online:
January 16 2009
Citation
David A. Davis, Irene R. Tebbs, Sarah I. Daniels, Stephen J. Stahl, Joshua D. Kaufman, Paul Wingfield, Michael J. Bowman, Jean Chmielewski, Robert Yarchoan; Analysis and characterization of dimerization inhibition of a multi-drug-resistant Human Immunodeficiency Virus Type 1 protease using a novel size-exclusion chromatographic approach. Biochem J 15 April 2009; 419 (2): 497–506. doi: https://doi.org/10.1042/BJ20082068
Download citation file:
Close
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Cited By
Related Articles
Crystal structures of plant inorganic pyrophosphatase, an enzyme with a moonlighting autoproteolytic activity
Biochem J (August,2019)
Biopanning of allergens from wasp sting patients
Biosci Rep (October,2018)
C-terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a putative protein receptor
Biochem J (March,2000)
Expression, purification and characterization of the monomeric and dimeric forms of soluble bovine endothelin converting enzyme-1a
Clin Sci (Lond) (September,2002)